Published in Nano Lett on July 08, 2008
Toxicity of nanomaterials. Chem Soc Rev (2011) 2.07
Widespread nanoparticle-assay interference: implications for nanotoxicity testing. PLoS One (2014) 0.96
Engineered nanomaterial uptake and tissue distribution: from cell to organism. Int J Nanomedicine (2013) 0.95
In vitro hematological and in vivo vasoactivity assessment of dextran functionalized graphene. Sci Rep (2013) 0.88
Advances in Systemic siRNA Delivery. Drugs Future (2009) 0.87
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) (2013) 0.85
Effects of long and short carboxylated or aminated multiwalled carbon nanotubes on blood coagulation. PLoS One (2012) 0.84
Ultrabright and multicolorful fluorescence of amphiphilic polyethyleneimine polymer dots for efficiently combined imaging and therapy. Sci Rep (2013) 0.83
Structural damage of chicken red blood cells exposed to platinum nanoparticles and cisplatin. Nanoscale Res Lett (2014) 0.82
Cytotoxicity of quantum dots and graphene oxide to erythroid cells and macrophages. Nanoscale Res Lett (2013) 0.81
In vivo safety evaluation of polyarginine coated magnetic nanovectors. Mol Pharm (2013) 0.80
Effects of magnetic cobalt ferrite nanoparticles on biological and artificial lipid membranes. Int J Nanomedicine (2014) 0.80
Analysis of SiO2 nanoparticles binding proteins in rat blood and brain homogenate. Int J Nanomedicine (2014) 0.79
Infiltration and sustenance of viability of cells by amphiphilic biosynthetic biodegradable hydrogels. J Mater Sci Mater Med (2014) 0.78
In vivo biodistribution studies and ex vivo lymph node imaging using heavy metal-free quantum dots. Biomaterials (2016) 0.77
Comparative in silico-in vivo evaluation of ASGP-R ligands for hepatic targeting of curcumin Gantrez nanoparticles. AAPS J (2013) 0.77
An Evaluation of Blood Compatibility of Silver Nanoparticles. Sci Rep (2016) 0.77
A structure-property relationship study of the well-defined telodendrimers to improve hemocompatibility of nanocarriers for anticancer drug delivery. Langmuir (2014) 0.76
Size Dependent Uptake and Hemolytic Effect of Zinc Oxide Nanoparticles on Erythrocytes and Biomedical Potential of ZnO-Ferulic acid Conjugates. Sci Rep (2017) 0.75
The cluster [Re6Se8I6]3- induces low hemolysis of human erythrocytes in vitro: protective effect of albumin. Int J Mol Sci (2015) 0.75
Biocompatibility of Bletilla striata Microspheres as a Novel Embolic Agent. Evid Based Complement Alternat Med (2015) 0.75
Shape-Related Toxicity of Titanium Dioxide Nanofibres. PLoS One (2016) 0.75
Encapsulation of Cardamom Essential Oil in Chitosan Nano-composites: In-vitro Efficacy on Antibiotic-Resistant Bacterial Pathogens and Cytotoxicity Studies. Front Microbiol (2016) 0.75
Threshold Dose of Three Types of Quantum Dots (QDs) Induces Oxidative Stress Triggers DNA Damage and Apoptosis in Mouse Fibroblast L929 Cells. Int J Environ Res Public Health (2015) 0.75
Interaction of graphene nanoribbons with components of the blood vascular system. Future Sci OA (2015) 0.75
An extracorporeal carbon dioxide removal (ECCO2R) device operating at hemodialysis blood flow rates. Intensive Care Med Exp (2017) 0.75
Triptolide and celastrol loaded silk fibroin nanoparticles show synergistic effect against human pancreatic cancer cells. Nanoscale (2017) 0.75
Immunological properties of engineered nanomaterials. Nat Nanotechnol (2007) 5.59
Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res (2003) 4.54
Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem (2004) 3.52
Characterization of aqueous dispersions of Fe(3)O(4) nanoparticles and their biomedical applications. Biomaterials (2005) 2.22
Nanotechnology for the biologist. J Leukoc Biol (2005) 2.03
Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm Res (2005) 1.21
Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target (2007) 1.14
Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm Res (2005) 1.09
Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm (2005) 1.03
Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials (1996) 1.03
Interaction of PLGA nanoparticles with human blood constituents. Colloids Surf B Biointerfaces (2005) 1.01
PVP magnetic nanospheres: biocompatibility, in vitro and in vivo bleomycin release. Int J Pharm (2006) 0.98
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol (2005) 0.98
PEI-based vesicle-polymer hybrid gene delivery system with improved biocompatibility. Int J Pharm (2004) 0.98
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol (2003) 0.97
In vitro hemolysis: guidance for the pharmaceutical scientist. J Pharm Sci (2006) 0.96
Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release (2004) 0.95
Polyethylenimine nanoparticles as efficient transfecting agents for mammalian cells. J Control Release (2005) 0.94
Blood compatibility of novel water soluble hyperbranched polyglycerol-based multivalent cationic polymers and their interaction with DNA. Biomaterials (2006) 0.91
Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles. Int J Pharm (2006) 0.91
A physicochemical approach for predicting the effectiveness of peptide-based gene delivery systems for use in plasmid-based gene therapy. Biophys J (1998) 0.91
[Destruction of human blood cells upon interaction with detonation nanodiamonds in experiments in vitro]. Biofizika (2005) 0.88
Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor- cycloheximide, for possible therapeutic applications. Curr Pharm Biotechnol (2005) 0.87
Medical nanotechnology: shortening clinical trials and regulatory pathways? BioDrugs (2005) 0.86
Lysis of human red blood cells. 4. Comparison of in vitro and in vivo hemolysis data. J Pharm Sci (1997) 0.86
Evaluation of aminoalkylmethacrylate nanoparticles as colloidal drug carrier systems. Part II: characterization of antisense oligonucleotides loaded copolymer nanoparticles. Eur J Pharm Biopharm (1999) 0.86
Effect of propofol and thiopentone on free radical mediated oxidative stress of the erythrocyte. Br J Anaesth (1996) 0.84
Lysis of human red blood cells 1: Effect of contact time on water induced hemolysis. PDA J Pharm Sci Technol (1996) 0.83
Lysis of human red blood cells. 3: Effect of contact time on surfactant-induced hemolysis. PDA J Pharm Sci Technol (1998) 0.83
Self-assembled drug delivery systems. 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (SAN). Int J Pharm (2005) 0.82
A novel, lipid-free nanodispersion formulation of propofol and its characterization. Pharm Res (2005) 0.81
In vitro study of the hemocompatibility of superparamagnetic contrast agent for magnetic resonance imaging. Clin Mater (1994) 0.80
Immunological properties of engineered nanomaterials. Nat Nanotechnol (2007) 5.59
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
Nanotechnology safety concerns revisited. Toxicol Sci (2007) 2.41
Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res (2002) 2.30
Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine (2008) 1.99
Characterization of nanoparticles for therapeutics. Nanomedicine (Lond) (2007) 1.62
Lipid bilayer disruption by polycationic polymers: the roles of size and chemical functional group. Langmuir (2005) 1.56
Detoxification of gold nanorods by treatment with polystyrenesulfonate. ACS Nano (2008) 1.42
HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem (2006) 1.36
Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr Biol (Camb) (2013) 1.30
Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.30
Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomedicine (2008) 1.28
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res (2012) 1.24
Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos (2008) 1.24
Induction of autophagy in porcine kidney cells by quantum dots: a common cellular response to nanomaterials? Toxicol Sci (2008) 1.23
Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction. Toxicol Appl Pharmacol (2010) 1.20
In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules (2004) 1.13
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res (2010) 1.12
Translational considerations for cancer nanomedicine. J Control Release (2010) 1.12
Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano- and submicron-size TiO2 particles. Toxicol Sci (2010) 1.11
Zeta potential measurement. Methods Mol Biol (2011) 1.10
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm (2011) 1.01
Adverse effects of fullerenes on endothelial cells: fullerenol C60(OH)24 induced tissue factor and ICAM-I membrane expression and apoptosis in vitro. Int J Nanomedicine (2008) 0.97
Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond) (2010) 0.95
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release (2013) 0.93
Detection and analysis of tumor fluorescence using a two-photon optical fiber probe. Biophys J (2004) 0.93
Measurement of 15N relaxation in deuterated amide groups in proteins using direct nitrogen detection. J Biomol NMR (2006) 0.92
Dendrimer-based BH3 conjugate that targets human carcinoma cells. Biomacromolecules (2007) 0.92
Activation of the MAP kinase cascade by exogenous calcium-sensing receptor. Mol Cell Endocrinol (2003) 0.89
Challenges and opportunities in the advancement of nanomedicines. J Control Release (2012) 0.89
SEM X-ray microanalysis of nanoparticles present in tissue or cultured cell thin sections. Methods Mol Biol (2011) 0.88
Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci (2014) 0.88
Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine (Lond) (2011) 0.87
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release (2013) 0.87
Molecular heterogeneity analysis of poly(amidoamine) dendrimer-based mono- and multifunctional nanodevices by capillary electrophoresis. Analyst (2006) 0.86
Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct. Mol Pharm (2010) 0.86
Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.86
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) (2013) 0.85
Spin-state selection for increased confidence in cross-correlation rates measurements. J Biomol NMR (2005) 0.85
Measuring the hydrodynamic size of nanoparticles in aqueous media using batch-mode dynamic light scattering. Methods Mol Biol (2011) 0.85
Analysis of poly(amidoamine)-succinamic acid dendrimers by slab-gel electrophoresis and capillary zone electrophoresis. Electrophoresis (2005) 0.85
Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Drug Deliv (2015) 0.83
Biological tissue and cell culture specimen preparation for TEM nanoparticle characterization. Methods Mol Biol (2011) 0.82
A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent. Invest Radiol (2013) 0.81
Choice of method for endotoxin detection depends on nanoformulation. Nanomedicine (Lond) (2013) 0.80
Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett (2013) 0.80
Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity. Nanomedicine (Lond) (2013) 0.80
Detecting and measuring free gadolinium in nanoparticles for MRI imaging. Methods Mol Biol (2011) 0.80
Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm (2013) 0.79
Chromatographic methods for the quantification of free and chelated gadolinium species in MRI contrast agent formulations. Anal Bioanal Chem (2010) 0.78
Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Biol Ther (2015) 0.78
Assay to detect lipid peroxidation upon exposure to nanoparticles. Methods Mol Biol (2011) 0.78
Biological applications of dendrimers. Mol Pharm (2012) 0.78
Tumor necrosis factor interaction with gold nanoparticles. Nanoscale (2012) 0.78
Biodistribution of nanomedicines. Mol Pharm (2008) 0.76
Analysis of fullerene-based nanomaterial in serum matrix by CE. Electrophoresis (2007) 0.75
Characterization of nanoparticles by matrix assisted laser desorption ionization time-of-flight mass spectrometry. Methods Mol Biol (2011) 0.75
Newkome-type dendron stabilized gold nanoparticles: Synthesis, reactivity, and stability. Chem Mater (2011) 0.75
Monitoring glutathione homeostasis in nanoparticle-treated hepatocytes. Methods Mol Biol (2011) 0.75
Lipid component quantitation by thin layer chromatography. Methods Mol Biol (2011) 0.75
Quantitative analysis of PEG-functionalized colloidal gold nanoparticles using charged aerosol detection. Anal Bioanal Chem (2015) 0.75